Table 15a. Persons living with diagnosed HIV infection, by year and selected characteristics, 2017-2021-United States. https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-34/content/tables.html (2021). Accessed.

Collaboration ATC. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. 2017;4(8):e349–56. https://doi.org/10.1016/s2352-3018(17)30066-8.

Article  Google Scholar 

Ghosn J, Taiwo B, Seedat S, Autran B, Katlama C. HIV Lancet. 2018;392(10148):685–97. https://doi.org/10.1016/s0140-6736(18)31311-4.

Article  PubMed  Google Scholar 

Verna EC. Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in patients with HIV. Lancet Gastroenterol Hepatol. 2017;2(3):211–23. https://doi.org/10.1016/s2468-1253(16)30120-0.

Article  PubMed  Google Scholar 

Cribbs SK, Crothers K, Morris A. Pathogenesis of HIV-related lung disease: immunity, infection, and inflammation. Physiol Rev. 2020;100(2):603–32. https://doi.org/10.1152/physrev.00039.2018.

Article  CAS  PubMed  Google Scholar 

Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis. 2011;53(11):1120–6. https://doi.org/10.1093/cid/cir627.

Article  PubMed  Google Scholar 

Nasi M, De Biasi S, Gibellini L, Bianchini E, Pecorini S, Bacca V, et al. Ageing and inflammation in patients with HIV infection. Clin Exp Immunol. 2017;187(1):44–52. https://doi.org/10.1111/cei.12814.

Article  CAS  PubMed  Google Scholar 

Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med. 2011;62:141–55. https://doi.org/10.1146/annurev-med-042909-093756.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5(10):e203. https://doi.org/10.1371/journal.pmed.0050203.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000;102(18):2165–8. https://doi.org/10.1161/01.cir.102.18.2165.

Article  CAS  PubMed  Google Scholar 

Shive CL, Jiang W, Anthony DD, Lederman MM. Soluble CD14 is a nonspecific marker of monocyte activation. AIDS. 2015;29(10):1263–5. https://doi.org/10.1097/qad.0000000000000735.

Article  CAS  PubMed  Google Scholar 

Sorgdrager FJH, Naudé PJW, Kema IP, Nollen EA, Deyn PP. Tryptophan metabolism in inflammaging: from biomarker to therapeutic target. Front Immunol. 2019;10:2565. https://doi.org/10.3389/fimmu.2019.02565.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schacker TW, Nguyen PL, Beilman GJ, Wolinsky S, Larson M, Reilly C, et al. Collagen deposition in HIV-1 infected lymphatic tissues and T cell homeostasis. J Clin Invest. 2002;110(8):1133–9. https://doi.org/10.1172/jci16413.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Masenga SK, Elijovich F, Koethe JR, Hamooya BM, Heimburger DC, Munsaka SM, et al. Hypertension and metabolic syndrome in persons with HIV. Curr Hypertens Rep. 2020;22(10):78. https://doi.org/10.1007/s11906-020-01089-3.

Article  PubMed  PubMed Central  Google Scholar 

Iyer N, Vaishnava S. Vitamin A at the interface of host-commensal-pathogen interactions. PLoS Pathog. 2019;15(6):e1007750. https://doi.org/10.1371/journal.ppat.1007750.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kelesidis T, Moser CB, Stein JH, Brown TT, Tran TT, Ribaudo HJ, et al. Changes in markers of t-cell senescence and exhaustion with HIV therapy. Topics in Antiviral Medicine. 2016;24(E-1):400.

Google Scholar 

Minami R, Takahama S, Yamamoto M. Correlates of telomere length shortening in peripheral leukocytes of HIV-infected individuals and association with leukoaraiosis. PLoS ONE. 2019;14(6):e0218996. https://doi.org/10.1371/journal.pone.0218996.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Montejano R, Stella-Ascariz N, Monge S, Bernardino JI, Pérez-Valero I, Montes ML, et al. Impact of nucleos(t)ide reverse transcriptase inhibitors on blood telomere length changes in a prospective cohort of aviremic HIV-infected adults. J Infect Dis. 2018;218(10):1531–40. https://doi.org/10.1093/infdis/jiy364.

Article  PubMed  Google Scholar 

Roy U, Matthews A, Kamkwalala AR, Garg A, Rodrigo H, Clifford D, et al. Tenofovir alafenamide is associated with shorter telomere length in people with HIV. Topics in Antiviral Medicine. 2022;30(1 SUPPL):245.

Google Scholar 

Walmsley S, Clarke R, Lee T, Singer J, Cheung AM, Smaill F, et al. BEING: bone health in aging women with HIV: impact of switching antiretroviral therapy on bone mineral density during the perimenopausal period. AIDS Res Hum Retroviruses. 2023;39(4):204–10. https://doi.org/10.1089/aid.2022.0106.

Article  CAS  PubMed  Google Scholar 

Minami R, Takahama S, Kaku Y, Yamamoto M. Risk factors of short telomere length and decreased mitochondrial DNA in HIV patients. Top Antiviral Med. 2016;24(E-1):277.

Google Scholar 

Serrano-Villar S, Martínez-Sanz J, Ron R, Talavera-Rodríguez A, Fernández-Felix BM, Herrera S, et al. Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study. Lancet HIV. 2020;7(8):e565–73. https://doi.org/10.1016/s2352-3018(20)30202-2.

Article  PubMed  Google Scholar 

Torres B, Guardo AC, Fabra A, Leal L, Rovira C, Hurtado C, et al. Effect of switching to raltegravir and/or adding losartan on HIV immune activation. Top Antiviral Med. 2018;26:125s-s126.

Google Scholar 

Serrano-Villar S, Martínez-Sanz J, Ron R, Talavera A, Fernández B, Fanjul F, et al. CD4/CD8 recovery and first-line art: greatest improvement with integrase inhibitors. Top Antiviral Med. 2020;28(1):167.

Google Scholar 

Masters MCC, Bao Y, Tassiopoulos K, Yang J, Overton ET, Letendre S, et al. Risk factors for progression from prediabetes to diabetes in persons with HIV. Top Antiviral Med. 2021;29(1):193–4.

Google Scholar 

Lahiri CD, Yu M, Gerig L, Mehta CC, Musonge-Effoe J, Price JC, et al. Liver steatosis and fibrosis in women with HIV by integrase inhibitor use. Top Antiviral Med. 2023;31(2):241.

Google Scholar 

Adachi E, Ikeuchi K, Koga M, Yotsuyanagi H. Changes in inflammatory biomarkers when switching from three-drug regimens to dolutegravir plus lamivudine in people living with HIV. AIDS Res Hum Retroviruses. 2022;38(12):881–3. https://doi.org/10.1089/aid.2022.0115.

Article  CAS  PubMed  Google Scholar 

Martínez-Sanz J, Ron R, Moreno E, Sánchez-Conde M, Muriel A, López Cortés LF, et al. Similar CD4/CD8 ratio recovery after initiation of dolutegravir plus lamivudine versus dolutegravir or bictegravir-based three-drug regimens in naive adults with HIV. Front Immunol. 2022;13:873408. https://doi.org/10.3389/fimmu.2022.873408.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Katlama. C. HIV-1 Infected Patients, Phase II Trial, Dual combination doravirine/raltegravir open label. https://classic.clinicaltrials.gov/show/NCT04513626; 2020.

Nakanjako D, Ssinabulya I, Nabatanzi R, Bayigga L, Kiragga A, Joloba M, et al. Atorvastatin reduces T-cell activation and exhaustion among HIV-infected cART-treated suboptimal immune responders in Uganda: a randomised crossover placebo-controlled trial. Trop Med Int Health. 2015;20(3):380–90. https://doi.org/10.1111/tmi.12442.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Negredo E, Jiménez M, Puig J, Loste C, Pérez-Álvarez N, Urrea V, et al. A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIV. PLoS ONE. 2020;15(9):e0238575. https://doi.org/10.1371/journal.pone.0238575.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Funderburg NT, Jiang Y, Debanne SM, Labbato D, Juchnowski S, Ferrari B, et al. Rosuvastatin reduces vascular inflammation and T-cell and monocyte activation in HIV-infected subjects on antiretroviral therapy. J Acquir Immune Defic Syndr. 2015;68(4):396–404. https://doi.org/10.1097/qai.0000000000000478.

Article  PubMed  PubMed Central  Google Scholar 

Hileman CO, Turner R, Funderburg NT, Semba RD, McComsey GA. Changes in oxidized lipids drive the improvement in monocyte activation and vascular disease after statin therapy in HIV. AIDS. 2016;30(1):65–73. https://doi.org/10.1097/qad.0000000000000885.

Article  CAS  PubMed  Google Scholar 

Eckard AR, Jiang Y, Debanne SM, Funderburg NT, McComsey GA. Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy. J Infect Dis. 2014;209(8):1156–64. https://doi.org/10.1093/infdis/jiu012.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Longenecker CT, Sattar A, Gilkeson R, McComsey GA. Rosuvastatin slows progression of subclinical atherosclerosis in patients with treated HIV infection. AIDS. 2016;30(14):2195–203. https://doi.org/10.1097/qad.0000000000001167.

Article  CAS  PubMed  Google Scholar 

Erlandson KM, Jiang Y, Debanne SM, McComsey GA. Effects of 96 weeks of rosuvastatin on bone, muscle, and fat in HIV-infected adults on effective antiretroviral therapy. AIDS Res Hum Retroviruses. 2016;32(4):311–6. https://doi.org/10.1089/aid.2015.0191.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hearps AC, Angelovich TA, Trevillyan JM, Wong ME, Calmy A, Hoy JF, et al. Effect